Indoco Remedies posts Q2 FY25 consolidated loss at Rs. 9.57 Cr
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Subscribe To Our Newsletter & Stay Updated